Liver protection by bis(maltolato)zinc(II) complex.

Area of Science:

• Pharmacology
• Hepatology
• Toxicology

Background:

• Liver injury is a significant health concern.
• Novel therapeutic agents are needed for liver protection.
• Bis(maltolato)zinc(II) complex [Zn(Mal)(2)] has shown insulinomimetic activity.

Purpose of the Study:

• To screen Bis(maltolato)zinc(II) complex [Zn(Mal)(2)] for hepatoprotective activity.
• To evaluate the efficacy of [Zn(Mal)(2)] against experimentally induced liver injury.
• To investigate the mechanisms underlying the hepatoprotective effects of [Zn(Mal)(2)].

Main Methods:

• In vitro: Cultured rat hepatocytes were treated with bromobenzene to induce injury, with varying concentrations of [Zn(Mal)(2)] added.
• In vivo: A concanavalin A-induced liver injury model in BALB/c mice was used to assess hepatoprotection.
• Measurements included hepatocyte viability, serum aminotransferase levels (AST, ALT), and cytokine secretion from splenocytes.

Main Results:

• In vitro, [Zn(Mal)(2)] maintained hepatocyte viability against bromobenzene-induced injury.
• In vivo, [Zn(Mal)(2)] suppressed the elevation of serum AST and ALT in concanavalin A-treated mice.
• While serum cytokines showed no significant change, [Zn(Mal)(2)] dose-dependently suppressed cytokine secretions from concanavalin A-stimulated mouse splenocytes.

Conclusions:

• Bis(maltolato)zinc(II) complex [Zn(Mal)(2)] exhibits significant hepatoprotective activity in vitro and in vivo.
• The compound may exert its protective effects through multiple mechanisms, including modulation of cytokine production.
• [Zn(Mal)(2)] represents a promising candidate for further development as a therapeutic agent for liver injury.